相似文献
1
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
Arthritis Res Ther. 2014 Dec 6;16(6):501. doi: 10.1186/s13075-014-0501-5.
2
[Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Dtsch Med Wochenschr. 2014 Nov;139(47):2399-404. doi: 10.1055/s-0034-1387371. Epub 2014 Nov 12.
3
[Implementation and use of biosimilars in the therapy of inflammatory rheumatic diseases: Statement of the German Society of Rheumatology].
Z Rheumatol. 2014 Nov;73(9):784-6. doi: 10.1007/s00393-014-1505-x.
4
Of patents and patent disputes: The TNFα patent files. Part 1: Humira.
Hum Antibodies. 2017;25(1-2):1-16. doi: 10.3233/HAB-160300.
5
Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
Acta Gastroenterol Belg. 2015 Jan-Mar;78(1):26-9.
6
Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Clin Exp Rheumatol. 2016 Jul-Aug;34(4):698-705. Epub 2016 Jul 4.
7
Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Immunotherapy. 2015;7(2):73-87. doi: 10.2217/imt.14.109.
8
Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi.
Hum Antibodies. 2018 Feb 5;26(2):49-61. doi: 10.3233/HAB-170321.
9
The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Expert Rev Clin Immunol. 2014 Aug;10(8):981-3. doi: 10.1586/1744666X.2014.932690. Epub 2014 Jun 25.
10
Biosimilar and interchangable biologic medications.
Geriatr Nurs. 2016 Sep-Oct;37(5):393-394. doi: 10.1016/j.gerinurse.2016.08.014. Epub 2016 Sep 13.
引用本文的文献
1
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment.
Cells. 2021 Feb 4;10(2):323. doi: 10.3390/cells10020323.
2
PANLAR consensus statement on biosimilars.
Clin Rheumatol. 2019 May;38(5):1485-1496. doi: 10.1007/s10067-019-04496-3. Epub 2019 Mar 27.
3
Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.
MAbs. 2018 Aug/Sep;10(6):827-842. doi: 10.1080/19420862.2018.1484977. Epub 2018 Aug 29.
4
Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
Clin Rheumatol. 2018 May;37(5):1143-1152. doi: 10.1007/s10067-018-3982-9. Epub 2018 Feb 6.
5
Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products.
MAbs. 2018 Jan;10(1):166-176. doi: 10.1080/19420862.2017.1387346. Epub 2017 Nov 7.
6
Latin-American challenges and opportunities in rheumatology.
Arthritis Res Ther. 2017 Feb 10;19(1):29. doi: 10.1186/s13075-017-1247-7.
7
Assessing the Immunogenicity of Biopharmaceuticals.
BioDrugs. 2016 Jun;30(3):195-206. doi: 10.1007/s40259-016-0174-5.
8
Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
Arthritis Rheumatol. 2016 May;68(5):1076-9. doi: 10.1002/art.39546.
9
Biosimilars in rheumatology: what the clinician should know.
RMD Open. 2015 May 23;1(1):e000010. doi: 10.1136/rmdopen-2014-000010. eCollection 2015.
10
Therapy: Facing up to biosimilar agents--the ACR position.
Nat Rev Rheumatol. 2015 Jun;11(6):322-4. doi: 10.1038/nrrheum.2015.57. Epub 2015 Apr 28.
本文引用的文献
1
Biosimilars in Crohn's disease.
J Crohns Colitis. 2014 Jul;8(7):710. doi: 10.1016/j.crohns.2013.12.002. Epub 2013 Dec 22.
2
Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.
MAbs. 2013 Sep-Oct;5(5):621-3. doi: 10.4161/mabs.25864. Epub 2013 Jul 24.
3
Biosimilars in rheumatology: perspective and concerns.
Rheumatology (Oxford). 2014 Mar;53(3):389-90. doi: 10.1093/rheumatology/ket210. Epub 2013 Jul 22.
4
Guidelines for the drug treatment of rheumatoid arthritis.
Rev Bras Reumatol. 2013 Apr;53(2):158-83.
5
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
Ann Rheum Dis. 2013 Oct;72(10):1613-20. doi: 10.1136/annrheumdis-2012-203090. Epub 2013 May 16.
6
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.
Ann Rheum Dis. 2013 Oct;72(10):1605-12. doi: 10.1136/annrheumdis-2012-203091. Epub 2013 May 16.
7
The role of biosimilars in the treatment of rheumatic diseases.
Ann Rheum Dis. 2013 Mar;72(3):322-8. doi: 10.1136/annrheumdis-2012-202715. Epub 2012 Dec 19.
8
Epoetin biosimilars in Europe: five years on.
Adv Ther. 2013 Jan;30(1):28-40. doi: 10.1007/s12325-012-0072-2. Epub 2012 Dec 12.
9
Biosimilars in rheumatology: a view from Latin America.
Clin Rheumatol. 2012 Sep;31(9):1279-80. doi: 10.1007/s10067-012-2068-3. Epub 2012 Aug 24.
10
The advent of biosimilar therapies in rheumatology--"O brave new world".
Nat Rev Rheumatol. 2012 Jun 5;8(7):430-6. doi: 10.1038/nrrheum.2012.84.
Zotero 插件